Summit Partners Public Asset Management LLC Increases Stock Position in Palvella Therapeutics, Inc. $PVLA

Summit Partners Public Asset Management LLC raised its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 1,016.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 389,420 shares of the company’s stock after purchasing an additional 354,525 shares during the quarter. Summit Partners Public Asset Management LLC owned 3.29% of Palvella Therapeutics worth $40,761,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Group One Trading LLC boosted its stake in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics during the 3rd quarter worth approximately $36,000. JPMorgan Chase & Co. boosted its stake in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter worth approximately $85,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter worth approximately $104,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

PVLA stock opened at $110.12 on Wednesday. Palvella Therapeutics, Inc. has a 1 year low of $20.20 and a 1 year high of $151.18. The stock’s 50 day moving average price is $119.12 and its 200 day moving average price is $108.76. The firm has a market cap of $1.58 billion, a P/E ratio of -26.41 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, research analysts predict that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PVLA shares. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. Mizuho boosted their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Stephens reissued an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. HC Wainwright boosted their price target on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Finally, Chardan Capital reissued a “buy” rating and set a $240.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $199.53.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.